Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine
NCT04829747
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
3
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Migraine
Interventions
DRUG:
Atogepant
Sponsor
Allergan